Targeted therapy with chemotherapy for resectable bile duct cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests a treatment for intrahepatic cholangiocarcinoma (a type of liver cancer) that can be surgically removed. It combines the usual chemotherapy drugs (cisplatin and gemcitabine) with the immunotherapy drug durvalumab, and compares it to the same regimen plus a targeted therapy called futibatinib, which works on specific genetic changes in the tumor. The goal is to see if adding the targeted therapy helps shrink the tumor before surgery and improves the outcome.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of intrahepatic cholangiocarcinoma (cancer starting in the bile ducts inside the liver) that is surgically removable and has not spread outside the liver or nearby lymph nodes.
- You have not had any prior treatment for this cancer (no chemotherapy, radiation, or other therapies).
- You are at least 18 years old and generally in good health (able to perform most daily activities, as per ECOG status 0-1).
- You have adequate organ function, which will be checked through blood tests (including kidney, liver, and blood cell counts).
- You must be able to swallow and take oral medications, and (if applicable) use effective contraception during and for several months after the study.
- You must not have certain medical conditions, such as uncontrolled heart disease, active eye (corneal or retinal) disorders, or a history of autoimmune disease or high-dose steroids.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy (gemcitabine and cisplatin) with the targeted therapy lenvatinib and the immunotherapy adebrelimab for people with advanced bile duct cancer that cannot be removed by surgery. It aims to see if this combination works better than standard treatments.
This trial combines a liver-directed radiation therapy (radioembolization) with a targeted drug to treat a specific type of bile duct cancer that cannot be surgically removed. The goal is to see if this combination can shrink the tumor and improve outcomes.
This study tests a combination of liver-directed therapy (D-TACE-HAIC), an immunotherapy drug (Envafolimab), and a targeted therapy pill (Lenvatinib) for people with a type of liver cancer (intrahepatic cholangiocarcinoma) that cannot be surgically removed. The goal is to see if this combination can shrink or control the cancer.
This trial tests if adding a combination of immunotherapy (adebrelimab), a targeted drug (apatinib), and chemotherapy into the liver artery (HAIC) before and after surgery can help people with resectable intrahepatic cholangiocarcinoma (a type of bile duct cancer). The goal is to see if this approach improves outcomes.
This trial tests combining a targeted radiation treatment (radioembolization) with two immunotherapy drugs (tremelimumab and durvalumab) for people with advanced intrahepatic cholangiocarcinoma that cannot be removed by surgery. It aims to shrink tumors and control cancer spread to lymph nodes or one other organ.
This trial tests a combination of targeted therapy, immunotherapy, and a liver-directed procedure (like chemoembolization) versus a standard chemotherapy cocktail for a type of bile duct cancer that is confined to the liver. It aims to see if the new combo can help patients live longer or slow the cancer down.
Hear when a new Resectable Intrahepatic Cholangiocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.